Sat, Aug 30, 2014, 12:49 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ZIOPHARM Oncology, Inc. Message Board

  • mrmainstreet mrmainstreet Mar 21, 2013 3:42 PM Flag

    Guess I'm just gun shy from DOX

    It over performed and killed the CLSN trial. What makes people so sure DOX by itself won't do better or the same as DOX with Z? Would love feedback from experienced ZIOP holders who know the science.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The Dox did not overperform in the CLSN trial. It's their Thermodelivery system that did not work like they have hoped. Additionally, they targeted one of the most difficult to treat cancer ( HCC), which has eluded effective treatment for several years now. ZIOP, on the otherhand, is basically using an already proven therapy for STS but making it much more tolerable for patients.

    • CLSN was just hooey. ZIOP is real science. Nothing similar other than they both were used in conjunction with DOX. The smart money was on failure in CLSN. ZIOP compound is biosimiliar to existing oncology Alkylating agents. The hope is that it will have a better toxicity profile and equal or better pfs and os data. Current alkylating agents are very toxic-- liver damage dementia, really bad stuff but they work (if you don't mind losing your mind in the process)

    • I plan to work til I drop so here we go rollem

 
ZIOP
3.23+0.08(+2.54%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.